CD1A and neoplasm: The sensitivity of the assay was determined by inspecting several samples derived from mixtures of two cell lines, one with the BRAF V600E mutation and another with wild-type BRAF.In addition, the results using this new method were compared with those from standard PCR and sequencing, and the two methods were evaluated using FFPE tissue section from LCH patients, the tumor content ratio determined by CD1a immunostaining.